Oral nanomedicines for the treatment of parasitic diseases

Katerina Lalatsa, Dolores Remedios Serrano Lopez, Lindsay Smith, Maria Auxiliadora Dea Ayuela

Research output: Contribution to conferencePosterpeer-review

55 Downloads (Pure)

Abstract

Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.
Original languageEnglish
Publication statusPublished - 15 Jul 2014
EventCRS Annual Meeting and Exposition - Chicago Hilton, Chicago, Illinois, United States
Duration: 12 Jul 201416 Jul 2014

Conference

ConferenceCRS Annual Meeting and Exposition
CountryUnited States
CityChicago, Illinois
Period12/07/1416/07/14

Fingerprint

Dive into the research topics of 'Oral nanomedicines for the treatment of parasitic diseases'. Together they form a unique fingerprint.

Cite this